Merck Commences P-IIb/III (BRUNELLO) Clinical Evaluation of Restoret to Treat Diabetic Macular Edema (DME)
Shots:
- Merck & EyeBio (Merck’s subsidiary) have commenced the P-IIb/III (BRUNELLO) study of Restoret as a treatment of DME, supported by the P-I/II (AMARONE) trial data in DME & neovascular age-related macular degeneration
- The P-IIb/III (BRUNELLO) study will investigate the safety & efficacy of two Restoret dose levels (intravitreal, Q4W) vs ranibizumab among DME patients, in ratio 1:1:1, for 1 yr. followed by a personalized treatment interval in the 2nd yr. The dual 1EP include safety & mean change in BCVA at wk.52
- Restoret is FIC tetravalent Wnt Ab that aims to restore the blood-retinal barrier and reduce vascular leakage by activating the Wnt pathway, as demonstrated in non-clinical studies
Ref: Merck | Image: Merck
Related News:- Merck Expands its Ophthalmologic Portfolio Through the Acquisition of EyeBio
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
